Key result
Post-PTCA estrogen therapy is linked to a ~62% lower risk of CV death or MI.
Why the study?
Estrogen replacement therapy suggests beneficial cardiovascular effects, but its impact on long-term outcomes after a first PTCA in postmenopausal women required assessment.
Does estrogen replacement therapy improve long-term outcomes in postmenopausal women after elective PTCA?
Cohort (n=337)
Does estrogen replacement therapy improve long-term outcomes in postmenopausal women after elective PTCA?
Answers are grounded in this paper and cite their sources.
In this retrospective cohort, estrogen replacement therapy was associated with improved long-term survival and reduced cardiovascular events in postmenopausal women following elective PTCA.
OBJECTIVES: The purpose of this study was to assess the effects of estrogen replacement therapy on long-term outcome, including restenosis, myocardial infarction, stroke and death after a first percutaneous transluminal coronary angioplasty (PTCA) procedure, in postmenopausal women. BACKGROUND: Observational and epidemiologic studies, basic laboratory research and clinical trials consistently suggest that estrogen replacement therapy is associated with beneficial cardiovascular effects in women. These cardioprotective actions may be particularly relevant to women with coronary artery disease, such as those who have undergone PTCA. METHODS: This was a retrospective study that included 337 women who underwent elective PTCA between 1982 and 1994. The treatment group consisted of 137 consecutive women receiving long-term estrogen therapy at the time of elective PTCA and during follow-up. The control group comprised 200 women who were computer-matched with the estrogen group. The mean follow-up period was 65 +/- 35 months. RESULTS: Actuarial survival was superior in the estrogen group; the 7-year survival rate was 93% for the estrogen group versus 75% for the control group (p = 0.001). The cardiovascular event rate (death, nonfatal myocardial infarction or nonfatal stroke) was significantly lower in the estrogen group at 7 years (12% vs. 35% in the control group, p = 0.001). The need for subsequent revascularization during follow-up was similar in the two groups. Multivariable analysis identified diabetes, estrogen therapy (adjusted risk ratio 0.38, 95% confidence interval 0.19 to 0.79) and left ventricular ejection fraction < 40% as independent correlates of cardiovascular death or myocardial infarction during follow-up. CONCLUSIONS: Estrogen replacement therapy was associated with an improved long-term outcome after PTCA in postmenopausal women.
No takes yet. Share an insight, caveat, or question.
O’Keefe et al. (1997) conducted a cohort in Coronary artery disease post-PTCA (n=337). Estrogen replacement therapy vs. No estrogen therapy was evaluated on Cardiovascular death or myocardial infarction (adjusted RR 0.38, 95% CI 0.19-0.79). Estrogen replacement therapy after PTCA in postmenopausal women was associated with a lower 7-year cardiovascular event rate (12% vs 35%, p=0.001) and reduced risk of CV death or MI (adjusted RR 0.38, 95% CI 0.19-0.79).
Synapse has enriched 10 related papers. Consider them for comparative context: